New treatment using injectable materials for heart attacks
Official title: Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI
Funded at Ventrix, INC. · NIH-10930015 · Data updated 2026-11-12
This study is testing a new type of injectable treatment for people who have had a heart attack, using special materials that help your body heal naturally without the need for complicated cell therapies, and it can be given through a small tube to make it safer and easier for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ventrix, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 15, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,440,231 |
| NIH project number | 5R44HL169072-02 |
| Project ID | NIH-10930015 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced an acute myocardial infarction and are at risk of developing heart failure.
✕Less likely to help
Patients who have not had a heart attack or those with advanced heart failure may not benefit from this research.
What this research studies
This research focuses on developing innovative injectable biomaterials to treat patients who have suffered from acute myocardial infarction (heart attacks). By utilizing acellular materials, the approach aims to stimulate the body's natural repair mechanisms without the complications associated with cell therapies. The treatment is designed to be delivered minimally invasively through catheters, making it a potentially safer and more cost-effective option for patients. The research builds on previous successes in creating similar injectable products for heart conditions.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients recovering from heart attacks, potentially improving heart function and reducing the risk of heart failure.
How similar studies have gone: Previous research has shown promise in using injectable biomaterials for heart conditions, indicating a potential for success with this novel approach.
Where this research is happening
-
Ventrix, INC.
San Diego, United States Active
Researchers
- Principal investigator: Kinsey, Adam M — Ventrix, INC.
- Study coordinator: Kinsey, Adam M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.